WO2020234445A1 - Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2 - Google Patents

Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2 Download PDF

Info

Publication number
WO2020234445A1
WO2020234445A1 PCT/EP2020/064262 EP2020064262W WO2020234445A1 WO 2020234445 A1 WO2020234445 A1 WO 2020234445A1 EP 2020064262 W EP2020064262 W EP 2020064262W WO 2020234445 A1 WO2020234445 A1 WO 2020234445A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
bcl
bet
dlbcl
bet inhibitor
Prior art date
Application number
PCT/EP2020/064262
Other languages
English (en)
Inventor
Mark D. DEMARIO
Fiona MACK
Valérie MERESSE NAEGELEN
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of WO2020234445A1 publication Critical patent/WO2020234445A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention is directed to the combination therapy of cancer, in particular of DLBCL, with a BET inhibitor and a Bcl-2 inhibitor.
  • B-cell lymphomas are much more common than T-cell lymphomas and account for approximately 85 percent of all Non-Hodgkin lymphomas (NHLs).
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for about 30 percent of newly diagnosed cases of NHL in the United States. DLBCL occurs in both men and women, although it is slightly more common in men. Although DLBCL can occur in childhood, its incidence generally increases with age, and roughly half of patients are over the age of 60.
  • DLBCL is an aggressive (fast-growing) lymphoma that can arise in lymph nodes or outside of the lymphatic system, in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain.
  • the first sign of DLBCL is a painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes.
  • the swelling may be painful.
  • Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain.
  • Relpased/refractory DLBCL accounts for approximately one third of patients with DLBCL. Approximately 50 to 60% of patients with DLBCL achieve and maintain complete remission after first-line therapy; 30 to 40% relapse and 10% have refractory disease. Patients with relapsing and refractory DLBCL (r/r DLBCL) have thus a poor outlook.
  • BET bromodomain and extra-terminal
  • Bcl-2 proteins play a role in many diseases, particularly in cancer, leukemia, immune and autoimmune diseases.
  • Bcl-2 proteins are said to be involved in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer.
  • Overexpression of Bcl-2 proteins correlate with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.
  • the invention thus relates in particular to:
  • the BET inhibitor and Bcl-2 inhibitor for use according to the invention wherein the BET inhibitor is 2-[(S)-4-(4-Chloro-phenyl)-2,3,9-trimethyl-6H-l-thia-5,7,8,9a-tetraaza- cyclopenta[e]azulen-6-yl]-N-[3-(4-methyl-piperazin-l-yl)-propyl]-acetamide (RG6146), INCB-054329, INCB-057643, GSK525762, GS-5829, CPI-0610, Birabresib, PLX51107, ABBV-075, BI 894999, FT-1101, ZEN-3694, GSK-2820151 or BMS-986158;
  • the BET inhibitor and Bcl-2 inhibitor for use according to the invention wherein the BET inhibitor is 2-[(S)-4-(4-Chloro-phenyl)-2,3,9-trimethyl-6H-l-thia-5,7,8,9a-tetraaza- cyclopenta[e]azulen-6-yl]-N-[3-(4-methyl-piperazin-l-yl)-propyl]-acetamide (RG6146);
  • the BET inhibitor and Bcl-2 inhibitor for use according to the invention wherein the Bcl-2 inhibitor is venetoclax, navitoclax, obatoclax, S-055746 or PNT-2258;
  • BET inhibitor and Bcl-2 inhibitor for use according to the invention, wherein the Bcl-2 inhibitor is venetoclax;
  • the BET inhibitor and a Bcl-2 inhibitor for use according to the invention comprising one or more additional other cytotoxic, chemotherapeutic or anti -cancer agents;
  • the BET inhibitor and a Bcl-2 inhibitor for use according to the invention comprising ionizing radiation enhancing the effects of said agents;
  • a pharmaceutical composition comprising a BET inhibitor and a Bcl-2 inhibitor and one or more pharmaceutically acceptable salt thereof for use in the treatment of DLBCL, in particular r/r DLBCL;
  • a method of treatment of DLBCL, in particular of r/r DLBCL, comprising the administration of a BET inhibitor and a Bcl-2 inhibitor to a patient in the need thereof;
  • a kit comprising a BET inhibitor and a Bcl-2 inhibitor for the simulatneous, separate or sequential administration of said BET inhibitor and Bcl-2 inhibitor;
  • kits according to the invention for use in the treatment of DLBCL, in particular r/r DLBCL;
  • the invention thus relates to a BET inhibitor and a Bcl-2 inhibitor for use in combination according to the invention.
  • the invention thus relates to a BET inhibitor and a Bcl-2 inhibitor for use in combination as a medicament, in particular for use in combination in the treatment of DLBCL, in particular r/r DLBCL.
  • the BET inhibitor is a compound selected from the compounds described in WO 2011/143669. Methods of producing said BET inhibitors are also disclosed in WO 2011/143669.
  • the BET inhibitor is 2-[(S)-4-(4-Chloro-phenyl)-2,3,9-trimethyl-6H- l-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-6-yl]-N-[3-(4-methyl-piperazin-l-yl)-propyl]- acetamide as in the formula below or a salt thereof.
  • Example JQ35 of WO 2011/143669 describes a method for its preparation.
  • the preferred BET inhibitor is depicted in the following formula:
  • the above BET inhibitor is also known as RG6146, JQ35 or TEN-010.
  • the Bcl-2 inhibitor is a compound selected from the compounds described in WO 2010/138588. Methods of producing said Bcl-2 inhibitors are also disclosed in WO 2010/138588. Most preferably, the Bcl-2 inhibitor is 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethyl cyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-( ⁇ 3-nitro-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl ⁇ sulfonyl)-2-(lH-pynOlo[2,3-b]pyridin-5-yloxy)benzamide as in the formula below or a salt thereof.
  • Example 5 of WO 2010/138588 describes methods for preparation of said Bcl-2 inhibitor.
  • the prefered Bcl-2 inhibitor is depicted in the following formula:
  • the above Bcl-2 inhibitor is also named ABT-199, GDC-0199 or venetoclax.
  • Figure 1 Overall best response (Lugano Criteria) for 23 patients receiving RG6146 and venetoclax combination treatment. Percentage change from baseline in Sum of Products of Perpendicular Diameters in Target Lesions, patients with post baseline target lesion measurement. Response according to PET-CT Lugano Classification.
  • BET inhibitor refers to an agent that prevents activity of BET proteins with an IC50 of about 0.001 mM to about 2 pM.
  • Bcl-2 inhibitor refers to an agent that prevents activity of Bcl-2 proteins with an IC50 of about 0.001 pM to about 2 pM
  • Salt refers to salts of the compounds as a pharmaceutically acceptable salt. Such salts can be exemplified by the salts with alkali metals (potassium, sodium, and the like), salts with alkaline-earth metals (calcium, magnesium, and the like), the ammonium salt, salts with pharmaceutically acceptable organic amines (tetramethylammonium,
  • IC50 refers to the concentration of a particular compound required to inhibit 50% of a specific measured activity.
  • a method of treating when applied to, for example, cancer refers to a procedure or course of action that is designed to reduce or eliminate the number of cancer cells in a patient, or to alleviate the symptoms of a cancer.
  • a method of treating does not necessarily mean that the cancer cells or other disorder will, in fact, be eliminated, that the number of cells or disorder will, in fact, be reduced, or that the symptoms of a cancer or other disorder will, in fact, be alleviated.
  • a method of treating cancer will be performed even with a low likelihood of success, but which, given the medical history and estimated survival expectancy of a patient, is nevertheless deemed to induce an overall beneficial course of action.
  • the terms“combination”,“co-administration” or“co-administering” refer to the administration of the BET inhibitor and the Bcl-2 inhibitor according to the invention in one or several formulations.
  • the co-administration can be simultaneous or sequential in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities.
  • the BET inhibitor and the Bcl-2 inhibitor can be co-administered either simultaneously or sequentially.
  • the dose can for example be administered either on the same day in three separate administrations, or one of the agents can be administered on day 1 and the second and third can be co-administered on day 2 to day 7, preferably on day 2 to 4.
  • the term“sequentially” means within 7 days after the dose of the first component, preferably within 4 days after the dose of the first component; and the term“simultaneously” means at the same time or on the same day.
  • the terms“co- admini strati on” with respect to the maintenance doses of the BET inhibitor and the Bcl-2 inhibitor mean that the maintenance doses can be either co-administered simultaneously, if the treatment cycle is appropriate for both drugs, e.g. every week. Or one of the
  • components can be administered e.g. every first to third day and the second component can be administered every week.
  • the maintenance doses are co-administered sequentially, either within one or within several days.
  • inhibitors are administered to the patient in a
  • therapeutically effective amount (or simply“effective amount”) which is the amount of the respective compound or combination that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the amount of co-administration of the the BET inhibitor and the Bcl-2 inhibitor and the timing of co-administration will depend on the type (species, gender, age, weight, etc.) and condition of the patient being treated and the severity of the disease or condition being treated.
  • the BET inhibitor is preferably administered subcutaneously.
  • the BET inhibitor is preferably administered at a dose between about 0.3 mg/kg/d and about 0.65 mg/kg/d.
  • the BET inhibitor is preferably administered daily for 14 consecutive days every 3 weeks (i.e. 2 weeks of dosing, 1 week of rest).
  • the BET inhibitor is preferably administered subcutaneously, at a dose between about 0.3 mg/kg/d and about 0.65 mg/kg/d.
  • the BET inhibitor is preferably administered subcutaneously, at a dose between about 0.3 mg/kg/d and about 0.65 mg/kg/d for 14 consecutive days every 3 weeks (i.e. 2 weeks of dosing, 1 week of rest).
  • the BET inhibitor is preferably RG6146.
  • the administration of the BET inhibitor, in particular RG6146 can be interrupted for up to 3 weeks, i.e 1, 2 or 3 weeks.
  • the Bcl-2 inhibitor is preferably administered oraly.
  • the Bcl-2 inhibitor is preferably administered at a dose between about 400 mg/d to about 800 mg/d, in particular 600 mg/d.
  • the Bcl-2 inhibitor is preferably administered oraly, at a dose between about 400 mg/d and about 800 mg/d, in particular 600 mg/d.
  • the Bcl-2 inhibitor is preferably administered daily (i.e. every day). This is called a continuous administration.
  • the Bcl-2 inhibitor is preferably daily administered oraly, at a dose between about 400 mg/d and about 800 mg/d, in particular 600 mg/d.
  • the Bcl-2 inhibitor is preferably venetoclax.
  • the administration cycles of the BET inhibitor and Bcl-2 inhibitor are preferably initiated on the same day.
  • the following amounts can be administered: about 0.3 mg/kg/d to about 0.65 mg/kg/d of the BET inhibitor, preferably RG6146; about 400 mg/d to about 800 mg/d, in particular 600 mg/d, of the Bcl-2 inhibitor, preferably venetoclax.
  • a particular advantageous combination is about 0.3 mg/kg/d to about 0.65 mg/kg/d of the BET inhibitor, preferably RG6146, every day for 14 consecutive days every 3 weeks (i.e. 2 weeks of dosing, 1 week of rest); about 400 mg/d to about 800 mg/d, in particular 600 mg/d, continuously (i.e. every day) of the Bcl-2 inhibitor, preferably venetoclax.
  • a further particular advantageous combination is about 0.3 mg/kg/d to about 0.65 mg/kg/d of the BET inhibitor, preferably RG6146, subcutaneously every day for 14 consecutive days every 3 weeks (i.e. 2 weeks of dosing, 1 week of rest); about 400 mg/d to about 800 mg/d, in particular 600 mg/d, continuously (i.e. every day) and oraly of the Bcl-2 inhibitor, preferably venetoclax.
  • the administration of the BET inhibitor, in particular RG6146 can be interrupted for up to 3 weeks, i.e 1, 2 or 3 weeks.
  • the administration of the Bcl-2 inhibitor, in particular venetoclax can be interrupted for up to 3 weeks, i.e 1, 2 or 3 weeks.
  • the recommended dose may vary when there is a further co-administration of a chemotherapeutic agent.
  • the administration of the BET inhibitor, in particular RG6146 can be interrupted for up to 3 weeks, i.e 1, 2 or 3 weeks.
  • the administration of the Bcl-2 inhibitor, in particular venetoclax can be interrupted for up to 3 weeks, i.e 1, 2 or 3 weeks.
  • the recommended dose may vary when there is a further co-administration of a chemotherapeutic agent.
  • the present invention is useful for preventing or reducing metastasis or further dissemination in such a patient suffering from DLBCL.
  • This invention is useful for increasing the duration of survival of such a patient, increasing the progression free survival of such a patient, increasing the duration of response, resulting in a statistically significant and clinically meaningful improvement of the treated patient as measured by the duration of survival, progression free survival, response rate or duration of response.
  • this invention is useful for increasing the response rate in a group of patients.
  • cytotoxic, chemotherapeutic or anti cancer agents or compounds or ionizing radiation that enhance the effects of such agents (e.g. cytokines) may be used.
  • cytokines cytotoxic, chemotherapeutic or anti cancer agents, or compounds or ionizing radiation that enhance the effects of such agents.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • Such additional agents include, for example: alkylating agents or agents with an alkylating action, such as cyclophosphamide (CTX; e.g. cytoxan®), chlorambucil (CHL; e.g. leukeran®), cisplatin (CisP; e.g. platinol®) busulfan (e.g. myleran®), melphalan, carmustine (BCNU), streptozotocin, triethylenemelamine (TEM), mitomycin C, and the like; anti-metabolites, such as methotrexate (MTX), etoposide (VP 16; e.g.
  • vepesid® 6- mercaptopurine (6MP), 6-thiocguanine (6TG), cytarabine (Ara-C), 5-fluorouracil (5-FU), capecitabine (e.g. Xeloda®), dacarbazine (DTIC), and the like; antibiotics, such as actinomycin D, doxorubicin (DXR; e.g.
  • adriamycin® daunorubicin (daunomycin), bleomycin, mithramycin and the like
  • alkaloids such as vinca alkaloids such as vincristine (VCR), vinblastine, and the like
  • antitumor agents such as paclitaxel (e.g.
  • paclitaxel derivatives the cytostatic agents, glucocorticoids such as dexamethasone (DEX; e.g. decadron®) and corticosteroids such as prednisone, nucleoside enzyme inhibitors such as hydroxyurea, amino acid depleting enzymes such as
  • arnifostine e.g.
  • ethyol® dactinomycin
  • mechlorethamine nitrogen mustard
  • streptozocin dactinomycin
  • cyclophosphamide lomustine (CCNU), doxorubicin lipo (e.g. doxil®), gemcitabine (e.g. gemzar®), daunorubicin lipo (e.g. daunoxome®), procarbazine, mitomycin, docetaxel (e.g.
  • taxotere® aldesleukin, carboplatin, oxaliplatin, cladribine, camptothecin, CPT 11 (irinotecan), 10-hydroxy 7-ethyl-camptothecin (SN38), floxuridine, fludarabine, ifosfamide, idarubicin, mesna, interferon beta, interferon alpha, mitoxantrone, topotecan, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, plicamycin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine or chlorambucil.
  • antiproliferative target-specific anticancer drugs like protein kinase inhibitors in
  • chemotherapeutic regimens is generally well characterized in the cancer therapy arts, and their use herein falls under the same considerations for monitoring tolerance and effectiveness and for controlling administration routes and dosages, with some
  • the actual dosages of the cytotoxic agents may vary depending upon the patient's cultured cell response determined by using histoculture methods.
  • the dosage will be reduced compared to the amount used in the absence of additional other agents.
  • Typical dosages of an effective cytotoxic agent can be in the ranges recommended by the manufacturer, and where indicated by in vitro responses or responses in animal models, can be reduced by up to about one order of magnitude concentration or amount.
  • the actual dosage will depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method based on the in vitro responsiveness of the primary cultured malignant cells or histocultured tissue sample, or the responses observed in the appropriate animal models.
  • an effective amount of ionizing radiation may be carried out and/or a radiopharmaceutical may be used.
  • the source of radiation can be either external or internal to the patient being treated.
  • the therapy is known as external beam radiation therapy (EBRT).
  • EBRT external beam radiation therapy
  • BT brachytherapy
  • Radioactive atoms for use in the context of this invention can be selected from the group including, but not limited to, radium, yttrium-90, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium-99, iodine-123, iodine-131, and indium-111. Is also possible to label the antibody with such radioactive isotopes.
  • Radiation therapy is a standard treatment for controlling unresectable or inoperable tumors and/or tumor metastases. Improved results have been seen when radiation therapy has been combined with chemotherapy. Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues.
  • the radiation dosage regimen is generally defined in terms of radiation absorbed dose (Gy), time and fractionation, and must be carefully defined by the oncologist.
  • the amount of radiation a patient receives will depend on various considerations, but the two most important are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which the tumor has spread.
  • a typical course of treatment for a patient undergoing radiation therapy will be a treatment schedule over a 1 to 6 week period, with a total dose of between 10 and 80 Gy
  • a "pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” is intended to include any and all material compatible with pharmaceutical administration including solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and other materials and compounds compatible with pharmaceutical administration. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • compositions can be obtained by processing the BET inhibitor inhibitor and the Bcl-2 inhibitor according to this invention with pharmaceutically acceptable, inorganic or organic carriers or excipients.
  • Lactose, corn starch or derivatives thereof, talc, stearic acids or it’s salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • compositions of the BET inhibitor inhibitor and the Bcl-2 inhibitor can be prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. (ed.) (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride;
  • phenol, butyl or benzyl alcohol alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEENTM,
  • compositions of the BET inhibitor and of the Bcl-2 inhibitor include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, as well as the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of a Bcl-2 inhibitor or a BET inhibitor which produces a therapeutic effect.
  • compositions Generally, out of one hundred percent, this amount will range from about 1 percent to about 90 percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • Methods of preparing these compositions include the step of bringing into association a Bcl-2 inhibitor or a BET inhibitor with the carrier and, optionally, one or more accessory ingredients.
  • the pharmaceutical compositions can be prepared by uniformaly and intimately bringing into association a Bcl-2 inhibitor and a BET inhibitor with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • compositions suitable for oral administration may be in the form of capsules, cachets, sachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a Bcl-2 inhibitor and a BET inhibitor as an active ingredient.
  • a Bcl-2 inhibitor and a BET inhibitor may also be administered as a bolus, electuary or paste.
  • the BET inhibitor inhibitor and the Bcl-2 inhibitor are formulated into one or two separate pharmaceutical compositions.
  • the active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interracial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules) or in
  • sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (US 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, non-degradable ethylene- vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the
  • LUPRON DEPOTTM injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
  • BET inhibitor RG6146 as single agent has been described for 13 response- evaluable r/r DLBCL patients treated in a phase 1 monotherapy study.
  • PRs partial responses
  • r/r DLBCL including transformed follicular lymphoma (tFL), with at least 1 prior regimen which included an anti-CD20 agent were eligible.
  • a 3 + 3 escalation design was used, RG6146 [(0.30, 0.45, or 0.65 mg/kg/d s.c. (14 d/3 wk cycle)] + venetoclax (400, 600, or 800 mg/d/3 wk cycle) to determine doublet maximum tolerated dose (MTD).
  • Doublet MTD was determined as 0.65 mg/kg RG6146 + 600 mg veneteoclax.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la polythérapie de DLBCL avec un inhibiteur de BET et un inhibiteur de Bcl-2.
PCT/EP2020/064262 2019-05-23 2020-05-22 Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2 WO2020234445A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851720P 2019-05-23 2019-05-23
US62/851,720 2019-05-23

Publications (1)

Publication Number Publication Date
WO2020234445A1 true WO2020234445A1 (fr) 2020-11-26

Family

ID=70847376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/064262 WO2020234445A1 (fr) 2019-05-23 2020-05-22 Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2

Country Status (1)

Country Link
WO (1) WO2020234445A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
WO2010138588A2 (fr) 2009-05-26 2010-12-02 Abbott Laboratories Agents induisant l'apoptose, dans le traitement du cancer et de maladies immunes et auto-immunes
WO2011143669A2 (fr) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions et méthodes de traitement des néoplasies, des maladies inflammatoires et d'autres affections
WO2018085069A1 (fr) * 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de bromodomaine pour le traitement du cancer
WO2019020606A1 (fr) * 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
WO2010138588A2 (fr) 2009-05-26 2010-12-02 Abbott Laboratories Agents induisant l'apoptose, dans le traitement du cancer et de maladies immunes et auto-immunes
WO2011143669A2 (fr) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions et méthodes de traitement des néoplasies, des maladies inflammatoires et d'autres affections
WO2018085069A1 (fr) * 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de bromodomaine pour le traitement du cancer
WO2019020606A1 (fr) * 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences 16th edition", 1980
ANONYMOUS: "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 - Tabular Vie", 8 January 2019 (2019-01-08), XP055711628, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT03255096> [retrieved on 20200703] *
ASTRID RUEFLIBRASSE: "Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy | Blood | American Society of Hematology", 7 December 2017 (2017-12-07), XP055711611, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/130/Supplement%201/2071/71135/Clinical-BET-Inhibitor-RG6146-Demonstrates-Potent> [retrieved on 20200703], DOI: 10.1182/blood.V130.Suppl_1.2071.2071 *
BATES JAMIE ET AL: "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines", vol. 128, no. 22, 2 December 2016 (2016-12-02), pages 1 - 6, XP009502459, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/128/22/5104> [retrieved on 20171218] *
FRANCESCO BERTONI ET AL: "Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies :", CURRENT OPINION IN HEMATOLOGY, vol. 26, no. 4, 1 July 2019 (2019-07-01), US, pages 273 - 280, XP055711605, ISSN: 1065-6251, DOI: 10.1097/MOH.0000000000000519 *
JAMIE BATES ET AL: "Figure 2 from Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines", BLOOD, vol. 128, no. 22, 2 December 2016 (2016-12-02), US, pages 5104 - 5104, XP055711857, ISSN: 0006-4971, DOI: 10.1182/blood.V128.22.5104.5104 *
MAI H. BUI ET AL: "Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies", CANCER RESEARCH, vol. 77, no. 11, 17 April 2017 (2017-04-17), AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, pages 2976 - 2989, XP055512277, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-1793 *
MS DAVIDS, J CLIN ONCOL, vol. 35, no. 8, 2017, pages 826 - 833
P. CAIMI, HEMATOLOGICAL ONE, vol. 35, no. S2, pages 263

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
TW200803892A (en) Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
JP2020505433A5 (fr)
EP3939610A1 (fr) Composition pharmaceutique combinée pour le traitement du cancer du poumon à petites cellules
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
US20200123153A1 (en) Combinations for immune-modulation in cancer treatment
WO2020249018A1 (fr) Composition pharmaceutique combinée pour le traitement du cancer du poumon positif aux gènes &#34;conducteurs&#34;
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
TW201909900A (zh) BET抑制劑、Bcl-2抑制劑及抗CD20抗體之組合療法
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
WO2016032882A1 (fr) Inhibition de mk2 dans le traitement du cancer
US20170173023A1 (en) Combination therapy with volasertib
WO2020234445A1 (fr) Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2
AU2005315912A1 (en) Novel pharmaceutical composition containing at least one Dolastatin 10 derivative
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
EP4144371A1 (fr) Médicament combiné pour le traitement du cancer du rein
WO2024051670A1 (fr) Combinaison pharmaceutique d&#39;anticorps se liant à tim-3 et d&#39;anticorps se liant à pd-1
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20727994

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20727994

Country of ref document: EP

Kind code of ref document: A1